{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:26:27Z","timestamp":1791260787375,"version":"4.1.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82503827"],"award-info":[{"award-number":["No. 82503827"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Project of Zhejiang Province","award":["No.2025C01107"],"award-info":[{"award-number":["No.2025C01107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02711-9","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:37:29Z","timestamp":1782373049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice"],"prefix":"10.1186","volume":"25","author":[{"given":"Shuyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"3","key":"2711_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2711_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2174\/1567201820666230731094258","volume":"21","author":"S Saini","year":"2024","unstructured":"Saini S, Gulati N, Awasthi R, et al. Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment. Curr Drug Deliv. 2024;21(7):993\u20131009. https:\/\/doi.org\/10.2174\/1567201820666230731094258.","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"2711_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49. https:\/\/doi.org\/10.1038\/s41392-024-02108-4.","journal-title":"Signal Transduct Target Ther"},{"key":"2711_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327. https:\/\/doi.org\/10.1016\/j.semcancer.2019.08.012.","journal-title":"Semin Cancer Biol"},{"issue":"Suppl 2","key":"2711_CR5","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast Edinb Scotl. 2015;24(Suppl 2):S26\u201335. https:\/\/doi.org\/10.1016\/j.breast.2015.07.008.","journal-title":"Breast Edinb Scotl"},{"issue":"10","key":"2711_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/biom14101219","volume":"14","author":"H Montazeri Aliabadi","year":"2024","unstructured":"Montazeri Aliabadi H. Molecular Targets for Breast Cancer Therapy. Biomolecules. 2024;14(10):1219. https:\/\/doi.org\/10.3390\/biom14101219.","journal-title":"Biomolecules"},{"issue":"6","key":"2711_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt K, Ullrich A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473\u201380. https:\/\/doi.org\/10.1038\/nrc2394.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2711_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2711_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"issue":"7","key":"2711_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"1","key":"2711_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"issue":"8","key":"2711_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380(8):741\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1814213.","journal-title":"N Engl J Med"},{"issue":"16","key":"2711_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"issue":"1","key":"2711_CR14","doi-asserted-by":"publisher","first-page":"188849","DOI":"10.1016\/j.bbcan.2022.188849","volume":"1878","author":"P Fan","year":"2023","unstructured":"Fan P, Xu K. Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low. Biochim Biophys Acta Rev Cancer. 2023;1878(1):188849. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188849.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"2711_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1871520616666160502122724","volume":"17","author":"S Nagini","year":"2017","unstructured":"Nagini S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 2017;17(2):152\u201363. https:\/\/doi.org\/10.2174\/1871520616666160502122724.","journal-title":"Anticancer Agents Med Chem"},{"issue":"12","key":"2711_CR16","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021;20(12):2329\u201340. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0206.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2711_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2174\/0115665240287767240115062343","volume":"25","author":"A Khalaji","year":"2025","unstructured":"Khalaji A, Hadad S, Jabbaripour Sarmadian A, Ojaghlou F, Janagard EM, Baradaran B. Advances in Monoclonal Antibody Therapies for Triple-Negative Breast Cancer: Immunotherapeutic and Targeted Strategies. Curr Mol Med. 2025;25(4):445\u201359. https:\/\/doi.org\/10.2174\/0115665240287767240115062343.","journal-title":"Curr Mol Med"},{"issue":"6","key":"2711_CR18","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(16)30030-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2711_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","volume":"14","author":"N Li","year":"2025","unstructured":"Li N, Yang L, Zhao Z, et al. Antibody-drug conjugates in breast cancer: current evidence and future directions. Exp Hematol Oncol. 2025;14(1):41. https:\/\/doi.org\/10.1186\/s40164-025-00632-9.","journal-title":"Exp Hematol Oncol"},{"key":"2711_CR20","doi-asserted-by":"publisher","unstructured":"Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1). https:\/\/doi.org\/10.1186\/s13045-020-00876-4.","DOI":"10.1186\/s13045-020-00876-4"},{"issue":"3","key":"2711_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203\u201323. https:\/\/doi.org\/10.1038\/s41571-023-00850-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"2711_CR22","doi-asserted-by":"publisher","first-page":"116709","DOI":"10.1016\/j.ejmech.2024.116709","volume":"276","author":"M Xi","year":"2024","unstructured":"Xi M, Zhu J, Zhang F, et al. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads. Eur J Med Chem. 2024;276:116709. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116709.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"2711_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/abt\/tby007","volume":"1","author":"Y Fu","year":"2018","unstructured":"Fu Y, Ho M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antib Ther. 2018;1(2):33\u201343. https:\/\/doi.org\/10.1093\/abt\/tby007.","journal-title":"Antib Ther"},{"issue":"7","key":"2711_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24(7):809\u201317. https:\/\/doi.org\/10.1007\/s11912-022-01266-4.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2711_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1535-7163.MCT-23-0622","volume":"23","author":"JD Thomas","year":"2024","unstructured":"Thomas JD, Yurkovetskiy AV, Yin M, et al. Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates. Mol Cancer Ther. 2024;23(4):541\u201351. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0622.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2711_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C. Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol. 2023;16(1):3. https:\/\/doi.org\/10.1186\/s13045-022-01397-y.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2711_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0.","journal-title":"Protein Cell"},{"issue":"40","key":"2711_CR28","doi-asserted-by":"publisher","first-page":"10282","DOI":"10.1002\/chem.202101373","volume":"27","author":"K Matinkhoo","year":"2021","unstructured":"Matinkhoo K, Wong AAWL, Hambira CM, et al. Design, Synthesis, and Biochemical Evaluation of Alpha-Amanitin Derivatives Containing Analogs of the trans-Hydroxyproline Residue for Potential Use in Antibody-Drug Conjugates. Chem Weinh Bergstr Ger. 2021;27(40):10282\u201392. https:\/\/doi.org\/10.1002\/chem.202101373.","journal-title":"Chem Weinh Bergstr Ger"},{"issue":"22","key":"2711_CR29","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","volume":"68","author":"GD Lewis Phillips","year":"2008","unstructured":"Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280\u201390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1776.","journal-title":"Cancer Res"},{"issue":"16","key":"2711_CR30","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh JD, Isidro-Llobet A, Parker JS, Spring DR. Cleavable linkers in antibody\u2013drug conjugates. Chem Soc Rev. 2019;48(16):4361\u201374. https:\/\/doi.org\/10.1039\/C8CS00676H.","journal-title":"Chem Soc Rev"},{"issue":"5","key":"2711_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab Deruxtecan: First Approval. Drugs. 2020;80(5):501\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01281-4.","journal-title":"Drugs"},{"issue":"5","key":"2711_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"2711_CR33","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0789.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2711_CR34","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1002\/cam4.4052","volume":"10","author":"WQ Li","year":"2021","unstructured":"Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med. 2021;10(14):4677\u201396. https:\/\/doi.org\/10.1002\/cam4.4052.","journal-title":"Cancer Med"},{"key":"2711_CR35","doi-asserted-by":"publisher","unstructured":"Dong W, Wang W, Cao C. The Evolution of Antibody-Drug Conjugates: Toward Accurate DAR and Multi-specificity. ChemMedChem. 2024;19(17). https:\/\/doi.org\/10.1002\/cmdc.202400109.","DOI":"10.1002\/cmdc.202400109"},{"issue":"8","key":"2711_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26(8):925\u201332. https:\/\/doi.org\/10.1038\/nbt.1480.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2711_CR37","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/bc500189z","volume":"25","author":"PM Drake","year":"2014","unstructured":"Drake PM, Albers AE, Baker J, et al. Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes. Bioconjug Chem. 2014;25(7):1331\u201341. https:\/\/doi.org\/10.1021\/bc500189z.","journal-title":"Bioconjug Chem"},{"issue":"52","key":"2711_CR38","doi-asserted-by":"publisher","first-page":"33510","DOI":"10.1039\/d2ra05630e","volume":"12","author":"A Hadjabdelhafid-Parisien","year":"2022","unstructured":"Hadjabdelhafid-Parisien A, Bitsch S, Palacios AM, Deweid L, Kolmar H, Pelletier JN. Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase. Rsc Adv. 2022;12(52):33510\u20135. https:\/\/doi.org\/10.1039\/d2ra05630e.","journal-title":"Rsc Adv"},{"issue":"11","key":"2711_CR39","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","volume":"26","author":"R van Geel","year":"2015","unstructured":"van Geel R, Wijdeven MA, Heesbeen R, et al. Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. Bioconjug Chem. 2015;26(11):2233\u201342. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00224.","journal-title":"Bioconjug Chem"},{"issue":"17","key":"2711_CR40","doi-asserted-by":"publisher","first-page":"5592","DOI":"10.1002\/anie.201814215","volume":"58","author":"K Yamada","year":"2019","unstructured":"Yamada K, Shikida N, Shimbo K, et al. AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies. Angew Chem-Int Ed. 2019;58(17):5592\u20137. https:\/\/doi.org\/10.1002\/anie.201814215.","journal-title":"Angew Chem-Int Ed"},{"key":"2711_CR41","doi-asserted-by":"publisher","unstructured":"Matsuda Y, Shikida N, Hatada N, et al. AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis. Org Lett. Published online April. 2024;19. https:\/\/doi.org\/10.1021\/acs.orglett.4c00878.","DOI":"10.1021\/acs.orglett.4c00878"},{"issue":"2","key":"2711_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/1568011053174846","volume":"5","author":"K Altundag","year":"2005","unstructured":"Altundag K, Esteva FJ, Arun B. Monoclonal antibody-based targeted therapy in breast cancer. Curr Med Chem Anti-Cancer Agents. 2005;5(2):99\u2013106. https:\/\/doi.org\/10.2174\/1568011053174846.","journal-title":"Curr Med Chem Anti-Cancer Agents"},{"issue":"10200","key":"2711_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(19)31774-X.","journal-title":"Lancet"},{"key":"2711_CR44","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed January 6, 2026."},{"key":"2711_CR45","unstructured":"National Medical Products Administration. NMPA Data Query. https:\/\/www.nmpa.gov.cn\/datasearch\/home-index.html#category=yp. Accessed January 6, 2026."},{"key":"2711_CR46","doi-asserted-by":"publisher","unstructured":"Mertins P, Mani D, Ruggles K, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605). https:\/\/doi.org\/10.1038\/nature18003.","DOI":"10.1038\/nature18003"},{"key":"2711_CR47","doi-asserted-by":"publisher","unstructured":"Cao J, Zhang Z, Zhou L, et al. Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy. MedComm. 2023;4(6). https:\/\/doi.org\/10.1002\/mco2.427.","DOI":"10.1002\/mco2.427"},{"key":"2711_CR48","doi-asserted-by":"publisher","first-page":"104683","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, Vempati R, Nagaraju GP, et al. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683. https:\/\/doi.org\/10.1016\/j.phrs.2020.104683.","journal-title":"Pharmacol Res"},{"issue":"13","key":"2711_CR49","doi-asserted-by":"publisher","first-page":"7208","DOI":"10.3390\/ijms25137208","volume":"25","author":"L Yang","year":"2024","unstructured":"Yang L, Hu Q, Huang T. Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert Cold Tumors to Hot Tumors. Int J Mol Sci. 2024;25(13):7208. https:\/\/doi.org\/10.3390\/ijms25137208.","journal-title":"Int J Mol Sci"},{"key":"2711_CR50","doi-asserted-by":"publisher","unstructured":"Mofunanya A, Cameron ER, Braun CJ, et al. Simultaneous screening of overexpressed genes in breast cancer for oncogenic drivers and tumor dependencies. Sci Rep. 2024;14(1). https:\/\/doi.org\/10.1038\/s41598-024-64297-w.","DOI":"10.1038\/s41598-024-64297-w"},{"issue":"1","key":"2711_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00335-026-10218-3","volume":"37","author":"MA Alshehri","year":"2026","unstructured":"Alshehri MA, Alissa M. Integrative immunogenomic and experimental characterization reveals CXCL9, CXCL13, CCL5 and CD74 as key oncogenic drivers in breast cancer. Mamm Genome Off J Int Mamm Genome Soc. 2026;37(1):50. https:\/\/doi.org\/10.1007\/s00335-026-10218-3.","journal-title":"Mamm Genome Off J Int Mamm Genome Soc"},{"issue":"4","key":"2711_CR52","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/2767-9764.CRC-24-0620","volume":"5","author":"D Liu","year":"2025","unstructured":"Liu D, Jee J, Drilon A, et al. Diverse ERBB2\/ERBB3 Activating Alterations and Coalterations Have Implications for HER2\/3-Targeted Therapies across Solid Tumors. Cancer Res Commun. 2025;5(4):680\u201393. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0620.","journal-title":"Cancer Res Commun"},{"issue":"6","key":"2711_CR53","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/cancers18060932","volume":"18","author":"Y Yamamoto","year":"2026","unstructured":"Yamamoto Y. Overcoming Trastuzumab\u2013Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer. Cancers. 2026;18(6):932. https:\/\/doi.org\/10.3390\/cancers18060932.","journal-title":"Cancers"},{"key":"2711_CR54","doi-asserted-by":"publisher","first-page":"102436","DOI":"10.1016\/j.ctrv.2022.102436","volume":"109","author":"JZ Drago","year":"2022","unstructured":"Drago JZ, Ferraro E, Abuhadra N, Modi S. Beyond HER2: Targeting the ErbB Receptor Family in Breast Cancer. Cancer Treat Rev. 2022;109:102436. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102436.","journal-title":"Cancer Treat Rev"},{"key":"2711_CR55","doi-asserted-by":"publisher","first-page":"15820","DOI":"10.3390\/ijms232415820","volume":"23","author":"SY Jun","year":"2022","unstructured":"Jun SY, Kim DS, Kim YS. Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity. Int J Mol Sci. 2022;23:15820. https:\/\/doi.org\/10.3390\/ijms232415820.","journal-title":"Int J Mol Sci"},{"issue":"10087","key":"2711_CR56","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet Lond Engl. 2017;389(10087):2415\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(16)32417-5.","journal-title":"Lancet Lond Engl"},{"key":"2711_CR57","doi-asserted-by":"publisher","unstructured":"Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treat Rev. 2025;132. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102861.","DOI":"10.1016\/j.ctrv.2024.102861"},{"key":"2711_CR58","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.ctrv.2021.102286","volume":"100","author":"E Hamilton","year":"2021","unstructured":"Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102286.","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"2711_CR59","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"issue":"3","key":"2711_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer","year":"2025","unstructured":"Geyer CE, Untch M, Huang CS, et al. Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. N Engl J Med. 2025;392(3):249\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2406070.","journal-title":"N Engl J Med"},{"issue":"12","key":"2711_CR61","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022;386(12):1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"issue":"10390","key":"2711_CR62","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andre","year":"2023","unstructured":"Andre F, Park YH, Kim SB, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial. Lancet. 2023;401(10390):1773\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(23)00725-0.","journal-title":"Lancet"},{"issue":"22","key":"2711_CR63","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024;391(22):2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407086.","journal-title":"N Engl J Med"},{"issue":"2","key":"2711_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","volume":"37","author":"N Harbeck","year":"2026","unstructured":"Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2026;37(2):166\u201379. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.019.","journal-title":"Ann Oncol"},{"issue":"9","key":"2711_CR65","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","volume":"394","author":"S Loibl","year":"2026","unstructured":"Loibl S, Park YH, Shao Z, et al. Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. N Engl J Med. 2026;394(9):845\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2514661.","journal-title":"N Engl J Med"},{"issue":"6","key":"2711_CR66","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026;394(6):551\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2508668.","journal-title":"N Engl J Med"},{"issue":"12 Suppl","key":"2711_CR67","doi-asserted-by":"publisher","first-page":"PS8","DOI":"10.1158\/1557-3265.SABCS24-PS8-06","volume":"31","author":"J Wang","year":"2025","unstructured":"Wang J, Ouyang Q, Xie W, et al. PS8-06: A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis. Clin Cancer Res. 2025;31(12 Suppl):PS8\u201306. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-PS8-06.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2711_CR68","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41523-023-00522-5","volume":"9","author":"J Zhang","year":"2023","unstructured":"Zhang J, Liu R, Gao S, et al. Phase I study of A166, an antibody\u2013drug conjugate in advanced HER2-expressing solid tumours. NPJ Breast Cancer. 2023;9(1):28. https:\/\/doi.org\/10.1038\/s41523-023-00522-5.","journal-title":"NPJ Breast Cancer"},{"key":"2711_CR69","doi-asserted-by":"publisher","first-page":"S1569","DOI":"10.1016\/j.annonc.2025.09.034","volume":"36","author":"X Hu","year":"2025","unstructured":"Hu X, Zhang J, Ouyang Q, et al. LBA24 Trastuzumab botidotin vs trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer: Results from a randomized phase III study. Ann Oncol. 2025;36:S1569. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.034.","journal-title":"Ann Oncol"},{"issue":"6","key":"2711_CR70","doi-asserted-by":"publisher","first-page":"e0326691","DOI":"10.1371\/journal.pone.0326691","volume":"20","author":"T Zhang","year":"2025","unstructured":"Zhang T, Xu J, Yin J, et al. SHR-A1811, a novel anti-HER2 antibody\u2013drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles. PLoS ONE. 2025;20(6):e0326691. https:\/\/doi.org\/10.1371\/journal.pone.0326691.","journal-title":"PLoS ONE"},{"key":"2711_CR71","doi-asserted-by":"publisher","first-page":"S1564","DOI":"10.1016\/j.annonc.2025.09.029","volume":"36","author":"E Song","year":"2025","unstructured":"Song E, Yao H, Li H, et al. LBA19 SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced\/metastatic breast cancer (BC): A multicenter, open-label, randomized, phase III study (HORIZON-Breast01). Ann Oncol. 2025;36:S1564\u20135. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.029.","journal-title":"Ann Oncol"},{"issue":"7","key":"2711_CR72","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/14728222.2025.2540355","volume":"29","author":"Y Ergun","year":"2025","unstructured":"Ergun Y. HER3 in breast cancer: molecular insights, clinical implications, and therapeutic horizons. Expert Opin Ther Targets. 2025;29(7):481\u20139. https:\/\/doi.org\/10.1080\/14728222.2025.2540355.","journal-title":"Expert Opin Ther Targets"},{"key":"2711_CR73","doi-asserted-by":"publisher","first-page":"102786","DOI":"10.1016\/j.ctrv.2024.102786","volume":"129","author":"F Papa","year":"2024","unstructured":"Papa F, Grinda T, Rassy E, et al. Long road towards effective HER3 targeting in breast cancer. Cancer Treat Rev. 2024;129:102786. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102786.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2711_CR74","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","volume":"82","author":"HM Haikala","year":"2022","unstructured":"Haikala HM, Lopez T, K\u00f6hler J, et al. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. Cancer Res. 2022;82(1):130\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2426.","journal-title":"Cancer Res"},{"issue":"10","key":"2711_CR75","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli B, Mosele F, Corcos N, et al. Patritumab deruxtecan in HR+HER2\u2009\u2013\u2009advanced breast cancer: a phase 2 trial. Nat Med. 2025;31(10):3492\u2013503. https:\/\/doi.org\/10.1038\/s41591-025-03885-3.","journal-title":"Nat Med"},{"issue":"5","key":"2711_CR76","doi-asserted-by":"publisher","first-page":"188789","DOI":"10.1016\/j.bbcan.2022.188789","volume":"1877","author":"X Li","year":"2022","unstructured":"Li X, Zhao L, Chen C, Nie J, Jiao B. Can EGFR be a therapeutic target in breast cancer? Biochim Biophys Acta Rev Cancer. 2022;1877(5):188789. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188789.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"2711_CR77","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","volume":"12","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhu Y, Qi D, Tang C, Zhang W. Trop2-targeted therapy in breast cancer. Biomark Res. 2024;12(1):82. https:\/\/doi.org\/10.1186\/s40364-024-00633-6.","journal-title":"Biomark Res"},{"key":"2711_CR78","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C, et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. N Engl J Med. 2025;393:1912\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2511734.","journal-title":"N Engl J Med"},{"issue":"12","key":"2711_CR79","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","volume":"30","author":"B Xu","year":"2024","unstructured":"Xu B, Wang S, Yan M, et al. Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med. 2024;30(12):3709\u201316. https:\/\/doi.org\/10.1038\/s41591-024-03269-z.","journal-title":"Nat Med"},{"issue":"3","key":"2711_CR80","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA, et al. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. J Clin Oncol Off J Am Soc Clin Oncol. 2025;43(3):285\u201396. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2711_CR81","doi-asserted-by":"publisher","first-page":"S1566","DOI":"10.1016\/j.annonc.2025.09.031","volume":"36","author":"RA Dent","year":"2025","unstructured":"Dent RA, Shao Z, Schmid P, et al. LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. Ann Oncol. 2025;36:S1566\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.031.","journal-title":"Ann Oncol"},{"issue":"6","key":"2711_CR82","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","volume":"31","author":"Y Yin","year":"2025","unstructured":"Yin Y, Fan Y, Ouyang Q, et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(6):1969\u201375. https:\/\/doi.org\/10.1038\/s41591-025-03630-w.","journal-title":"Nat Med"},{"key":"2711_CR83","doi-asserted-by":"publisher","first-page":"S1568","DOI":"10.1016\/j.annonc.2025.09.033","volume":"36","author":"Y Fan","year":"2025","unstructured":"Fan Y, Li H, Wang H, et al. LBA23 Sacituzumab tirumotecan (sac-TMT) vs investigator\u2019s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2-) breast cancer (BC): Results from the randomized, multi-center phase III OptiTROP-Breast02 study. Ann Oncol. 2025;36:S1568\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.033.","journal-title":"Ann Oncol"},{"issue":"10","key":"2711_CR84","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016;76(10):3003\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313.","journal-title":"Cancer Res"},{"key":"2711_CR85","doi-asserted-by":"publisher","first-page":"176129","DOI":"10.1016\/j.ejphar.2023.176129","volume":"960","author":"H Wang","year":"2023","unstructured":"Wang H, Sun D, Chen J, Li H, Chen L. Nectin-4 has emerged as a compelling target for breast cancer. Eur J Pharmacol. 2023;960:176129. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176129.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"2711_CR86","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","volume":"34","author":"JE Rosenberg","year":"2023","unstructured":"Rosenberg JE, Powles T, Sonpavde GP, et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2023;34(11):1047\u201354. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.016.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"2711_CR87","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/nu4070648","volume":"4","author":"BJ Grattan","year":"2012","unstructured":"Grattan BJ, Freake HC. Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients. 2012;4(7):648\u201375. https:\/\/doi.org\/10.3390\/nu4070648.","journal-title":"Nutrients"},{"issue":"2","key":"2711_CR88","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1042\/BJ20130483","volume":"455","author":"C Hogstrand","year":"2013","unstructured":"Hogstrand C, Kille P, Ackland ML, Hiscox S, Taylor KM. A mechanism for epithelial-mesenchymal transition and anoikis resistance in breast cancer triggered by zinc channel ZIP6 and STAT3 (signal transducer and activator of transcription 3). Biochem J. 2013;455(2):229\u201337. https:\/\/doi.org\/10.1042\/BJ20130483.","journal-title":"Biochem J"},{"issue":"4","key":"2711_CR89","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11033-008-9225-4","volume":"36","author":"H Shen","year":"2009","unstructured":"Shen H, Qin H, Guo J. Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7. Mol Biol Rep. 2009;36(4):653\u20139. https:\/\/doi.org\/10.1007\/s11033-008-9225-4.","journal-title":"Mol Biol Rep"},{"issue":"12","key":"2711_CR90","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1158\/1535-7163.MCT-13-0896","volume":"13","author":"D Sussman","year":"2014","unstructured":"Sussman D, Smith LM, Anderson ME, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014;13(12):2991\u20133000. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0896.","journal-title":"Mol Cancer Ther"},{"key":"2711_CR91","doi-asserted-by":"publisher","unstructured":"Yu J, Yan Y, Li S, et al. Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. Cell. 2024;187(17). https:\/\/doi.org\/10.1016\/j.cell.2024.06.012.","DOI":"10.1016\/j.cell.2024.06.012"},{"issue":"2","key":"2711_CR92","doi-asserted-by":"publisher","first-page":"153","DOI":"10.36401\/JIPO-24-34","volume":"8","author":"M Phipps","year":"2025","unstructured":"Phipps M, Falchook GS. B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review. J Immunother Precis Oncol. 2025;8(2):153\u201360. https:\/\/doi.org\/10.36401\/JIPO-24-34.","journal-title":"J Immunother Precis Oncol"},{"key":"2711_CR93","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.annonc.2024.08.673","volume":"35","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Naito Y, Gaillard S, et al. 606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced\/metastatic solid tumors. Ann Oncol. 2024;35:S485\u20136. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.673.","journal-title":"Ann Oncol"},{"issue":"2","key":"2711_CR94","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","volume":"45","author":"MH Andersen","year":"2023","unstructured":"Andersen MH. Tumor microenvironment antigens. Semin Immunopathol. 2023;45(2):253\u201364. https:\/\/doi.org\/10.1007\/s00281-022-00966-0.","journal-title":"Semin Immunopathol"},{"issue":"12","key":"2711_CR95","doi-asserted-by":"publisher","first-page":"e005543","DOI":"10.1136\/jitc-2022-005543","volume":"10","author":"M Yi","year":"2022","unstructured":"Yi M, Wu Y, Niu M, et al. Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10(12):e005543. https:\/\/doi.org\/10.1136\/jitc-2022-005543.","journal-title":"J Immunother Cancer"},{"issue":"23","key":"2711_CR96","doi-asserted-by":"publisher","first-page":"16771","DOI":"10.3390\/ijms242316771","volume":"24","author":"MA Dom\u00ednguez-Cejudo","year":"2023","unstructured":"Dom\u00ednguez-Cejudo MA, Gil-Torralvo A, Cejuela M, Molina-Pinelo S, Salvador Bofill J. Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities. Int J Mol Sci. 2023;24(23):16771. https:\/\/doi.org\/10.3390\/ijms242316771.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2711_CR97","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3390\/cells9081826","volume":"9","author":"A Vaidya","year":"2020","unstructured":"Vaidya A, Wang H, Qian V, Gilmore H, Lu ZR. Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells. Cells. 2020;9(8):1826. https:\/\/doi.org\/10.3390\/cells9081826.","journal-title":"Cells"},{"issue":"9","key":"2711_CR98","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","volume":"21","author":"AT Hooper","year":"2022","unstructured":"Hooper AT, Marquette K, Chang CPB, et al. Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade. Mol Cancer Ther. 2022;21(9):1462\u201372. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0099.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2711_CR99","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","volume":"13","author":"S Shahvali","year":"2023","unstructured":"Shahvali S, Rahiman N, Jaafari MR, Arabi L. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res. 2023;13(7):2041\u201356. https:\/\/doi.org\/10.1007\/s13346-023-01308-9.","journal-title":"Drug Deliv Transl Res"},{"issue":"1","key":"2711_CR100","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41467-024-47068-z","volume":"15","author":"H Croizer","year":"2024","unstructured":"Croizer H, Mhaidly R, Kieffer Y, et al. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nat Commun. 2024;15(1):2806. https:\/\/doi.org\/10.1038\/s41467-024-47068-z.","journal-title":"Nat Commun"},{"key":"2711_CR101","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jconrel.2024.02.014","volume":"367","author":"M Bocci","year":"2024","unstructured":"Bocci M, Zana A, Principi L, et al. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. J Control Release Off J Control Release Soc. 2024;367:779\u201390. https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.014.","journal-title":"J Control Release Off J Control Release Soc"},{"issue":"14","key":"2711_CR102","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang X, Lin Y, Shi Y, et al. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res. 2016;76(14):4124\u201335. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2973.","journal-title":"Cancer Res"},{"issue":"9","key":"2711_CR103","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1158\/0008-5472.CAN-21-3734","volume":"82","author":"U Ray","year":"2022","unstructured":"Ray U, Pathoulas CL, Thirusangu P, Purcell JW, Kannan N, Shridhar V. Exploiting LRRC15 as a Novel Therapeutic Target in Cancer. Cancer Res. 2022;82(9):1675\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3734.","journal-title":"Cancer Res"},{"issue":"1","key":"2711_CR104","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3892\/mmr.2021.12518","volume":"25","author":"Y Yang","year":"2022","unstructured":"Yang Y, Wu H, Fan S, Bi Y, Hao M, Shang J. Cancer\u2013associated fibroblast\u2013derived LRRC15 promotes the migration and invasion of triple\u2013negative breast cancer cells via Wnt\/\u03b2\u2013catenin signalling pathway regulation. Mol Med Rep. 2022;25(1):2. https:\/\/doi.org\/10.3892\/mmr.2021.12518.","journal-title":"Mol Med Rep"},{"issue":"2","key":"2711_CR105","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/pharmaceutics17020258","volume":"17","author":"P Ballest\u00edn","year":"2025","unstructured":"Ballest\u00edn P, L\u00f3pez de S\u00e1 A, D\u00edaz-Tejeiro C, et al. Understanding the Toxicity Profile of Approved ADCs. Pharmaceutics. 2025;17(2):258. https:\/\/doi.org\/10.3390\/pharmaceutics17020258.","journal-title":"Pharmaceutics"},{"issue":"D1","key":"2711_CR106","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53(D1):D1670\u20136. https:\/\/doi.org\/10.1093\/nar\/gkae973.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2711_CR107","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20(8):558\u201376. https:\/\/doi.org\/10.1038\/s41571-023-00783-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"2711_CR108","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer. Breast Edinb Scotl. 2022;66:169\u201377. https:\/\/doi.org\/10.1016\/j.breast.2022.10.007.","journal-title":"Breast Edinb Scotl"},{"issue":"1","key":"2711_CR109","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama M, Tada M, Yokoo H, Demizu Y, Ishii-Watabe A. Fc\u03b3 Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates. Pharm Res. 2022;39(1):89\u2013103. https:\/\/doi.org\/10.1007\/s11095-021-03158-x.","journal-title":"Pharm Res"},{"key":"2711_CR110","doi-asserted-by":"publisher","unstructured":"Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. Esmo Open. 2022;7(4). https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","DOI":"10.1016\/j.esmoop.2022.100554"},{"key":"2711_CR111","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.008.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"2711_CR112","doi-asserted-by":"publisher","first-page":"e18579","DOI":"10.1002\/anie.202518579","volume":"65","author":"D Cai","year":"2026","unstructured":"Cai D, Zhao Y, Lu G, et al. Efficient Preparation of Homogenous Antibody Conjugates via Glycosite-Specific Transglycosylation Enabled by Readily Available Glycosyl Donors. Angew Chem Int Ed Engl. 2026;65(7):e18579. https:\/\/doi.org\/10.1002\/anie.202518579.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2711_CR113","doi-asserted-by":"publisher","first-page":"118114","DOI":"10.1016\/j.ejmech.2025.118114","volume":"300","author":"X Zheng","year":"2025","unstructured":"Zheng X, Zhao Y, Miao Y, Zheng C. Pyrrolobenzodiazepine dimers for chemotherapy and antibody-drug conjugate applications. Eur J Med Chem. 2025;300:118114. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118114.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"2711_CR114","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1158\/1535-7163.MCT-22-0440","volume":"22","author":"BM Bordeau","year":"2023","unstructured":"Bordeau BM, Nguyen TD, Polli JR, Chen P, Balthasar JP. Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates. Mol Cancer Ther. 2023;22(4):459\u201370. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0440.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2711_CR115","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","volume":"9","author":"J Fuentes-Antr\u00e1s","year":"2023","unstructured":"Fuentes-Antr\u00e1s J, Genta S, Vijenthira A, Siu LL. Antibody-drug conjugates: in search of partners of choice. Trends Cancer. 2023;9(4):339\u201354. https:\/\/doi.org\/10.1016\/j.trecan.2023.01.003.","journal-title":"Trends Cancer"},{"key":"2711_CR116","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2019.10.023","volume":"72","author":"M Benvenuto","year":"2021","unstructured":"Benvenuto M, Focaccetti C, Izzi V, Masuelli L, Modesti A, Bei R. Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Semin Cancer Biol. 2021;72:65\u201375. https:\/\/doi.org\/10.1016\/j.semcancer.2019.10.023.","journal-title":"Semin Cancer Biol"},{"key":"2711_CR117","doi-asserted-by":"publisher","first-page":"107687","DOI":"10.1016\/j.phrs.2025.107687","volume":"214","author":"X Liu","year":"2025","unstructured":"Liu X, Fan X, Gao X, Hu W, Sun P. Leveraging HER2-targeted biparatopic antibodies in solid tumors. Pharmacol Res. 2025;214:107687. https:\/\/doi.org\/10.1016\/j.phrs.2025.107687.","journal-title":"Pharmacol Res"},{"issue":"3","key":"2711_CR118","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/antib9030049","volume":"9","author":"J Cheng","year":"2020","unstructured":"Cheng J, Liang M, Carvalho MF, et al. Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody. Antibodies. 2020;9(3):49. https:\/\/doi.org\/10.3390\/antib9030049.","journal-title":"Antibodies"},{"key":"2711_CR119","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.ctrv.2024.102826","volume":"130","author":"X Liu","year":"2024","unstructured":"Liu X, Song Y, Cheng P, Liang B, Xing D. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes. Cancer Treat Rev. 2024;130:102826. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102826.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2711_CR120","doi-asserted-by":"publisher","first-page":"2310890","DOI":"10.1080\/19420862.2024.2310890","volume":"16","author":"DL Niquille","year":"2024","unstructured":"Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. mAbs. 2024;16(1):2310890. https:\/\/doi.org\/10.1080\/19420862.2024.2310890.","journal-title":"mAbs"},{"issue":"16 Suppl","key":"2711_CR121","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2024.42.16_suppl.3038","volume":"42","author":"JJ Park","year":"2024","unstructured":"Park JJ, Gao B, Beecroft C, et al. Safety and efficacy of JSKN003 in patients with advanced\/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study. J Clin Oncol. 2024;42(16 Suppl):3038\u20133038. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3038.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"2711_CR122","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1200\/JCO.2025.43.16_suppl.5557","volume":"43","author":"X Wu","year":"2025","unstructured":"Wu X, Chen Y, Rao Q, et al. JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials. J Clin Oncol. 2025;43(16 Suppl):5557\u20135557. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5557.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2711_CR123","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-025-04863-9","volume":"96","author":"X Ji","year":"2026","unstructured":"Ji X, Yang Y, Ma C, et al. Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. Cancer Chemother Pharmacol. 2026;96(1):15. https:\/\/doi.org\/10.1007\/s00280-025-04863-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2711_CR124","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41467-026-69456-3","volume":"17","author":"M Yi","year":"2026","unstructured":"Yi M, Li T, Gu Y, et al. Triple targeting of STING, TGF-\u03b2, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response. Nat Commun. 2026;17(1):1441. https:\/\/doi.org\/10.1038\/s41467-026-69456-3.","journal-title":"Nat Commun"},{"key":"2711_CR125","doi-asserted-by":"publisher","unstructured":"Tao J, Gu Y, Zhou W, Wang Y. Dual-payload antibody-drug conjugates: Taking a dual shot. Eur J Med Chem. 2025;281. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116995.","DOI":"10.1016\/j.ejmech.2024.116995"},{"issue":"7","key":"2711_CR126","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","volume":"21","author":"KS Saini","year":"2021","unstructured":"Saini KS, Punie K, Twelves C, et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther. 2021;21(7):945\u201362. https:\/\/doi.org\/10.1080\/14712598.2021.1936494.","journal-title":"Expert Opin Biol Ther"},{"issue":"43","key":"2711_CR127","doi-asserted-by":"publisher","first-page":"e2408598","DOI":"10.1002\/advs.202408598","volume":"11","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, et al. Blockade of CCR5\u2009+\u2009T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-\u03b2\/PD-L1 Bispecific Antibody. Adv Sci. 2024;11(43):e2408598. https:\/\/doi.org\/10.1002\/advs.202408598.","journal-title":"Adv Sci"},{"issue":"2","key":"2711_CR128","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10549-021-06423-0","volume":"191","author":"TET Roussos","year":"2022","unstructured":"Roussos TET, Emens LA. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody\u2013drug conjugates and bispecific antibodies. Breast Cancer Res Treat. 2022;191(2):291\u2013302. https:\/\/doi.org\/10.1007\/s10549-021-06423-0.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"2711_CR129","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/abt\/tbaf017","volume":"8","author":"L Yin","year":"2025","unstructured":"Yin L, Zhou S, Zhang H, et al. Reprogramming the tumor microenvironment: synergistic mechanisms of antibody\u2013drug conjugates and immune checkpoint inhibitors. Antib Ther. 2025;8(3):262. https:\/\/doi.org\/10.1093\/abt\/tbaf017.","journal-title":"Antib Ther"},{"key":"2711_CR130","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/ITT.S495751","volume":"14","author":"C Corti","year":"2025","unstructured":"Corti C, Koca B, Rahman T, Mittendorf EA, Tolaney SM. Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer. ImmunoTargets Ther. 2025;14:339\u201357. https:\/\/doi.org\/10.2147\/ITT.S495751.","journal-title":"ImmunoTargets Ther"},{"issue":"8","key":"2711_CR131","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(8):983\u201393. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.355.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2711_CR132","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.556","volume":"34","author":"P Schmid","year":"2023","unstructured":"Schmid P, Wysocki PJ, Ma CX, et al. 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Updated results from BEGONIA, a phase Ib\/II study. Ann Oncol. 2023;34:S337. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.556.","journal-title":"Ann Oncol"},{"key":"2711_CR133","doi-asserted-by":"publisher","first-page":"S413","DOI":"10.1016\/j.annonc.2025.08.978","volume":"36","author":"P Schmid","year":"2025","unstructured":"Schmid P, Wang HC, Lynce F, et al. 555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Final results from the phase Ib\/II BEGONIA study. Ann Oncol. 2025;36:S413\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.978.","journal-title":"Ann Oncol"},{"issue":"3","key":"2711_CR134","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","volume":"46","author":"Y Hong","year":"2023","unstructured":"Hong Y, Nam SM, Moon A. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Arch Pharm Res. 2023;46(3):131\u201348. https:\/\/doi.org\/10.1007\/s12272-023-01433-6.","journal-title":"Arch Pharm Res"},{"key":"2711_CR135","doi-asserted-by":"publisher","unstructured":"Jin S, Sun Y, Liang X, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022;7(1). https:\/\/doi.org\/10.1038\/s41392-021-00868-x.","DOI":"10.1038\/s41392-021-00868-x"},{"key":"2711_CR136","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"B Chen","year":"2025","unstructured":"Chen B, Zheng X, Wu J, et al. Antibody\u2013drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025;24:279. https:\/\/doi.org\/10.1186\/s12943-025-02489-2.","journal-title":"Mol Cancer"},{"issue":"18","key":"2711_CR137","doi-asserted-by":"publisher","first-page":"e172156","DOI":"10.1172\/JCI172156","volume":"133","author":"HL Chang","year":"2023","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. 2023;133(18):e172156. https:\/\/doi.org\/10.1172\/JCI172156.","journal-title":"J Clin Invest"},{"issue":"3","key":"2711_CR138","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Y, Shao Z, Yu K. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun. 2022;43(3):297\u2013337. https:\/\/doi.org\/10.1002\/cac2.12387.","journal-title":"Cancer Commun"},{"issue":"5","key":"2711_CR139","doi-asserted-by":"publisher","first-page":"189396","DOI":"10.1016\/j.bbcan.2025.189396","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Horne D, Salgia R, Singhal SS. Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochim Biophys Acta BBA - Rev Cancer. 2025;1880(5):189396. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189396.","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"issue":"6","key":"2711_CR140","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/CCO.0000000000001087","volume":"36","author":"L Guidi","year":"2024","unstructured":"Guidi L, Boldrini L, Trapani D, Curigliano G. Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances. Curr Opin Oncol. 2024;36(6):487\u201394. https:\/\/doi.org\/10.1097\/CCO.0000000000001087.","journal-title":"Curr Opin Oncol"},{"key":"2711_CR141","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-3-031-70875-6_24","volume":"1464","author":"J Veeraraghavan","year":"2025","unstructured":"Veeraraghavan J, De Angelis C, Gutierrez C, et al. HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025;1464:495\u2013525. https:\/\/doi.org\/10.1007\/978-3-031-70875-6_24.","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"2711_CR142","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2174\/13894501113149990161","volume":"14","author":"Y Huang","year":"2013","unstructured":"Huang Y, Fu P, Fan W. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer. Curr Drug Targets. 2013;14(8):889\u201398. https:\/\/doi.org\/10.2174\/13894501113149990161.","journal-title":"Curr Drug Targets"},{"issue":"3 Suppl 3","key":"2711_CR143","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1053\/j.seminoncol.2008.01.006","volume":"35","author":"M Kavallaris","year":"2008","unstructured":"Kavallaris M, Annereau JP, Barret JM. Potential mechanisms of resistance to microtubule inhibitors. Semin Oncol. 2008;35(3 Suppl 3):S22\u201327. https:\/\/doi.org\/10.1053\/j.seminoncol.2008.01.006.","journal-title":"Semin Oncol"},{"issue":"11","key":"2711_CR144","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. 2023;24(11):9674. https:\/\/doi.org\/10.3390\/ijms24119674.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2711_CR145","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.nano.2016.10.005","volume":"13","author":"PE Saw","year":"2017","unstructured":"Saw PE, Park J, Jon S, Farokhzad O. A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin. Nanomed Nanotechnol Biol Med. 2017;13(2):713\u201322. https:\/\/doi.org\/10.1016\/j.nano.2016.10.005.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"2711_CR146","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","volume":"11","author":"I Valle","year":"2025","unstructured":"Valle I, Grinda T, Antonuzzo L, Pistilli B. Antibody\u2013drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives. NPJ Breast Cancer. 2025;11(1):102. https:\/\/doi.org\/10.1038\/s41523-025-00829-5.","journal-title":"NPJ Breast Cancer"},{"key":"2711_CR147","doi-asserted-by":"publisher","first-page":"101288","DOI":"10.1016\/j.drup.2025.101288","volume":"83","author":"GY Wu","year":"2025","unstructured":"Wu GY, Xiao MZ, Hao WC, et al. Drug resistance in breast cancer: Mechanisms and strategies for management. Drug Resist Updat. 2025;83:101288. https:\/\/doi.org\/10.1016\/j.drup.2025.101288.","journal-title":"Drug Resist Updat"},{"key":"2711_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-025-01752-9","volume":"18","author":"K Zhou","year":"2025","unstructured":"Zhou K, Liu X, Zhu H. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025;18:1\u201343. https:\/\/doi.org\/10.1186\/s13045-025-01752-9.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2711_CR149","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"C Yu-Fei","year":"2023","unstructured":"Yu-Fei C, Ying-ying X, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun. 2023;43(3):297\u2013337. https:\/\/doi.org\/10.1002\/cac2.12387.","journal-title":"Cancer Commun"},{"issue":"16","key":"2711_CR150","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","volume":"27","author":"ML Maitland","year":"2021","unstructured":"Maitland ML, Sachdev JC, Sharma MR, et al. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody\u2013Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clin Cancer Res. 2021;27(16):4511\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3757.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2711_CR151","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","volume":"23","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Novello S, Bearz A, et al. Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022;23(4):540\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(22)00061-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2711_CR152","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41523-021-00244-6","volume":"7","author":"LT Vahdat","year":"2021","unstructured":"Vahdat LT, Schmid P, Forero-Torres A, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (METRIC): a randomized multicenter study. NPJ Breast Cancer. 2021;7(1):57. https:\/\/doi.org\/10.1038\/s41523-021-00244-6.","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"2711_CR153","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02711-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02711-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02711-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:46:25Z","timestamp":1789080385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02711-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2711"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02711-9","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"215"}}